2 citations
,
October 2021 in “Journal of Cosmetic Dermatology” Finasteride is more effective and satisfactory than montelukast for treating moderate acne in women.
2 citations
,
August 2011 in “Cochrane Database of Systematic Reviews”
January 2011 in “Side effects of drugs annual” Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
July 2013 in “Edinburgh Research Archive (University of Edinburgh)” Dutasteride may reduce insulin sensitivity and increase body fat.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
5 citations
,
May 2011 in “Movement Disorders” Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.
5 citations
,
May 2011 in “Movement Disorders” Finasteride may help reduce tic severity in male Tourette syndrome patients.
July 2023 in “World Journal of Biology Pharmacy and Health Sciences” Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
26 citations
,
June 2005 in “Journal of Molecular Endocrinology” Dutasteride is more efficient than finasteride, but individual results vary.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
Finasteride reduces DHT to treat prostate issues and hair loss.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
March 2012 in “Society for Endocrinology BES 2012” A new method was developed to analyze certain hormones and drugs in human blood efficiently.
May 2022 in “Endocrine Abstracts” Finasteride may cause sexual dysfunction by reducing epinephrine levels.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
11 citations
,
April 2018 in “Journal of Dermatology” Dutasteride safely treats hair loss without harming sexual function.
14 citations
,
January 2003 in “Actas Urológicas Españolas” Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
15 citations
,
January 2018 in “Acta dermato-venereologica” Finasteride and dutasteride increase sexual dysfunction risk by 1.57 times in male hair loss treatment.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
The research developed new fortilin protein constructs for potential heart disease treatments.
February 2023 in “Reactions Weekly” September 2019 in “Hair transplant forum international” Using finasteride may increase the risk of erectile dysfunction.
February 2026 in “European Urology”
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
January 2025 in “Current Trends in Pharmacy and Pharmaceutical Chemistry” New methods for measuring dutasteride are effective and reliable.